The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple near-term catalysts. Heading into July, here are three US-listed GLP-1 names worth a closer look, each with a tool-verified data point, a bull case, and a clear risk.
Eli Lilly (LLY): The Category Killer
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the franchise stock of the GLP-1 era, and the price action reflects it. Shares are up nearly 15% year to date and more than 60% over the past year, with a market cap of roughly $1.16 trillion as of July 7
Q1 2026 was a statement quarter. Lilly posted EPS of $8.55 versus the $6.79 consensus on revenue of $19.80 billion, up 56% year over year. Mounjaro generated $8.66 billion (+125% YoY) and Zepbound delivered $4.16 billion (+80% YoY). Management raised full-year guidance to $82.0 billion to $85.0 billion in revenue and $35.50 to $37.00 in non-GAAP EPS
The bull case rests on a one-two punch: injectable dominance plus the only oral pill with no food/water restriction. CEO David Ricks said “A key milestone was the U.S. FDA approval of Foundayo, the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s.”
Risk: Realized prices fell 13% in Q1 2026 due to rebate adjustments and market-access agreements, and Mounjaro’s NRDL addition in China is pressuring international pricing. Revenue concentration in two products remains the obvious vulnerability
Novo Nordisk (NVO): The Beaten-Down Incumbent
Novo Nordisk (NYSE:NVO) is the contrarian pick. The maker of Ozempic, Wegovy and Rybelsus is down nearly 28% over the past year, with a market cap of around $169 billion. Per writer context, shares trade at roughly 10x earnings and sit near 45% below their 52-week high. Note that NVO is an ADR, so dividends are subject to Danish withholding tax at source
Sentiment is beginning to shift. Reddit’s aggregate score on NVO flipped to 63 (Bullish) on June 30, up from readings of 22-29 (Bearish) in early June, and shares have rebounded more than 2% over the past month
The bull case is valuation-driven. NVO posts elite margins (gross margin near 81%, operating margin around 41%) and remains one of only two players with a commercial oral GLP-1 already on the market. If the company stabilizes US share against Lilly, mean reversion alone offers material upside
Risk: Novo has been steadily losing ground to Mounjaro and Zepbound, and Jim Cramer recently noted Lilly’s pipeline could deliver “the unassailable knockout punch against Novo Nordisk because it’s got fat busting without muscle crunch.” A value trap is the obvious failure mode
Viking Therapeutics (VKTX): The High-Risk Wild Card
Viking Therapeutics (NASDAQ:VKTX) is explicitly the speculative slot. Market cap sits at about $4.7 billion, and shares have rallied nearly 38% over the past month, with a one-year gain of nearly 47%
Lead asset VK2735 is a dual GLP-1/GIP receptor agonist in both subcutaneous and oral formulations. The Phase 2 oral readout showed up to 12% mean body weight reduction after 13 weeks. VANQUISH-1 is fully enrolled with approximately 4,500 patients, and the Phase 3 oral program is expected to begin in Q3 2026, with maintenance dosing results also due that quarter. Cash and investments stood at roughly $706 million at year-end 2025
CEO Brian Lian framed the differentiation as “the only dual agonist molecule with the potential to dose monthly or to allow transition from subcutaneous to oral administration for weight maintenance.”
Risk: Viking is pre-revenue, with a 2025 net loss of $359.64 million and a cash position that fell from $903 million at the start of 2025 to $706 million at year-end. Phase 3 readouts could land either way, and a single negative trial would reset the equity story
What to Watch Next
July’s setup is event-rich: Lilly’s Foundayo launch metrics, Novo’s competitive response, and Viking’s Q3 catalyst calendar. Position sizing matters across the three, because the risk profiles are not interchangeable. The GLP-1 trade is broadening, and the opportunity set looks wider than at any point in the last twelve months
Contact [email protected] for any questions or corrections
